N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide has been researched along with brivanib in 1 studies
| Studies (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Trials (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Recent Studies (post-2010) (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Studies (brivanib) | Trials (brivanib) | Recent Studies (post-2010) (brivanib) |
|---|---|---|---|---|---|
| 9 | 0 | 7 | 86 | 19 | 71 |
| Protein | Taxonomy | N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide (IC50) | brivanib (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.028 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.068 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.38 | |
| Vascular endothelial growth factor receptor 2 | Mus musculus (house mouse) | 0.089 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0255 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide and brivanib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |